WO2000045814A1 - Methods and compositions to enhance white blood cell count - Google Patents

Methods and compositions to enhance white blood cell count Download PDF

Info

Publication number
WO2000045814A1
WO2000045814A1 PCT/CA2000/000104 CA0000104W WO0045814A1 WO 2000045814 A1 WO2000045814 A1 WO 2000045814A1 CA 0000104 W CA0000104 W CA 0000104W WO 0045814 A1 WO0045814 A1 WO 0045814A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylene
subject
formula
bis
phenylenebis
Prior art date
Application number
PCT/CA2000/000104
Other languages
French (fr)
Inventor
Ronald Trevor Macfarland
Andrew W. Miller
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0007924-3A priority Critical patent/BR0007924A/en
Priority to DK00903441T priority patent/DK1148875T3/en
Application filed by Anormed Inc. filed Critical Anormed Inc.
Priority to DE60011391T priority patent/DE60011391T2/en
Priority to MXPA01007801A priority patent/MXPA01007801A/en
Priority to AT00903441T priority patent/ATE268597T1/en
Priority to JP2000596934A priority patent/JP4968868B2/en
Priority to EP00903441A priority patent/EP1148875B1/en
Priority to NZ513602A priority patent/NZ513602A/en
Priority to CA2361587A priority patent/CA2361587C/en
Priority to AU25278/00A priority patent/AU772979B2/en
Priority to APAP/P/2001/002221A priority patent/AP1497A/en
Priority to SI200030444T priority patent/SI1148875T1/en
Priority to CNB008033285A priority patent/CN1310642C/en
Priority to IL144400A priority patent/IL144400A/en
Publication of WO2000045814A1 publication Critical patent/WO2000045814A1/en
Priority to NO20013770A priority patent/NO20013770L/en
Priority to HK02100103.2A priority patent/HK1038319B/en
Priority to AU2004203847A priority patent/AU2004203847B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the invention is in the field of therapeutics and medicinal chemistry. More particularly, the invention concerns methods to enhance white blood cell counts in subjects by administering certain cyclic polyamines.
  • White blood cells play a significant part in maintaining the health and viability of animals, including humans. These white blood cells include neutrophils, macrophage, and basophils/mast cells as well the B and T cells of the immune system. White blood cells are continuously replaced (as are red blood cells and clot forming cells) by the hematopoietic system in response to a number of growth factors, such as colony stimulating factors (CSF) and various cytokines. The nucleotide sequences encoding a number of these growth factors have been cloned and sequenced. Perhaps the most widely known of these is granulocyte colony stimulating factor (G-CSF) which has been approved for use in counteracting the negative effects of chemotherapy. A discussion of the hematopoietic effects of this factor can be found, for example, in U.S. Patent No. 5,582,823, incorporated in its entirety by reference herein.
  • G-CSF granulocyte colony stimulating factor
  • the invention is directed to methods of treating animal subjects, in particular, veterinary and human patients, who are defective in white blood cell (WBC) count, or who would benefit from elevation of WBC levels.
  • WBC white blood cell
  • the methods of the invention employ cyclic polyamines including those described in the patents incorporated hereinabove by reference.
  • the invention is directed to a method to elevate the white blood cells (WBC) count, in a subject in need of such WBC elevation, which method comprises administering to said subject an amount of a compound of formula (1) or of a pharmaceutical composition thereof effective to elevate WBC levels.
  • WBC white blood cells
  • the invention is directed to pharmaceutical compositions containing the compound of formula (1) for use in effecting WBC count elevation in animal subject.
  • the compounds of formula (1) are of the formula:
  • Z-linker-Z' (1) wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms; said nitrogen atoms separated from each other by at least 2 carbon atoms, wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system.
  • Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula -N(R)-(CR 2 ) n -X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and
  • X is an aromatic ring, including heteroaromatic rings, or is a mercaptan;
  • linker represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
  • Figure 1 is a graph showing the response of individual human patients to intravenous administration of a compound of the invention.
  • Figure 2 is a graph showing the response in elevation of WBC counts observed in HIV-infected patients who received AMD-3100 by continuous infusion for up to 10 consecutive days.
  • the compounds useful in the invention are of the general formula set forth as formula (1) above. Certain embodiments are preferred; included among these are the compounds set forth in the above-incorporated U.S. patents.
  • preferred embodiments of Z and Z' are cyclic polyamine moieties having from 9-24C that include 3-5 nitrogen atoms.
  • 1,5,9,13-tetraazacyclohexadecane 1,5,8,11,14-pentaazacyclohexadecane; 1,4,8,11- tetraazacylotetradecane; 1 ,5,9-triazacylcododecane; 1 ,4,7, 10-tetraazacyclododecane; and the like, including such cyclic polyamines which are fused to an additional aromatic or heteroaromatic rings and/or containing a heteroatom other than nitrogen incorporated in the ring.
  • the cyclic polyamine contains a fused additional cyclic system or one or more additional heteroatoms are described in U.S. Patent No. 5,698,546 incorporated hereinabove by reference. Also preferred are
  • Z' is other than a cyclic polyamine as defined in Z
  • its preferred embodiments are set forth in U.S. Patent No. 5,817,807, also incorporated hereinabove by reference.
  • linker moiety examples include those wherein the linker is a bond, or wherein the linker includes an aromatic moiety flanked by alkylene, preferably methylene moieties.
  • Preferred linking groups include the methylene bracketed forms of 1,3-phenylene, 2,6-pyridine, 3,5-pyridine, 2,5-thiophene, 4,4'-(2,2'-bipyrimidine); 2,9-( 1 , 10-phenanthroline) and the like.
  • a particularly preferred linker is 1,4- phenylene-bis-(methylene).
  • Particularly preferred embodiments of the compound of the formula (1) include 2,2'-bicyclam; 6,6'-bicyclam; the embodiments set forth in U.S. Patent No. 5,583,131, and in particular l,l'-[l,4-phenylene-bis(methylene)]-bis- 1,4,8,11- tetraazacyclotetradecane, set forth in U.S. Patent No. 5,021,409, and designated herein AMD3100.
  • the compounds of the invention may be prepared in the form of prodrugs, i.e., protected forms which release the compounds of the invention after administration to the subject.
  • the protecting groups are hydrolyzed in body fluids such as in the bloodstream thus releasing the active compound or are oxidized or reduced in vivo to release the active compound.
  • a discussion of prodrugs is found in Smith and Williams Introduction to the Principles of Drug Design, Smith, H.J.; Wright, 2 nd ed., London (1988).
  • the compounds of the invention may be administered prepared in the forms of their acid addition salts or metal complexes thereof.
  • Suitable acid addition salts include salts of inorganic acids that are biocompatible, including HC1, HBr, sulfuric, phosphoric and the like, as well as organic acids such as acetic, propionic, butyric and the like, as well as acids containing more than one carboxyl group, such as oxalic, glutaric, adipic and the like.
  • the compounds of the invention will be in the forms of the acid addition salts. Particularly preferred are the hydrobromides.
  • the compounds when prepared as purified forms, the compounds may also be crystallized as the hydrates.
  • the compounds of the invention may be administered as sole active ingredients, as mixtures of various compounds of formula (1), and/or in admixture with additional active ingredients that are therapeutically or nutritionally useful, such as antibiotics, vitamins, herbal extracts, antiinflammatori.es, glucose, antipyretics, analgesics, and the like.
  • the compounds of the invention may be formulated for administration to animal subject using commonly understood formulation techniques well known in the art. Formulations which are suitable for particular modes of administration and for compounds of the type represented by those of formula (1) may be found in
  • the compounds are administered by injection, most preferably by intravenous injection, but also by subcutaneous or intraperitoneal injection, and the like.
  • Additional parenteral routes of administration include intramuscular and intraarticular injection.
  • the compounds are formulated in suitable liquid form with excipients as required.
  • the compositions may contain liposomes or other suitable carriers.
  • the solution is made isotonic using standard preparations such as Hank's solution.
  • other routes of administration may also be used.
  • the compounds may be formulated into tablets, capsules, syrups, powders, or other suitable forms for administration orally.
  • suitable excipients these compounds may also be administered through the mucosa using suppositories or intranasal sprays.
  • Transdermal administration can also be effected by using suitable penetrants and controlling the rate of release.
  • Suitable dosage ranges for the compounds of formula (1) vary according to these considerations, but in general, the compounds are administered in the range of about 0.1 ⁇ g/kg-5 mg/kg of body weight; preferably the range is about 1 ⁇ g/kg - 300 ⁇ g/kg of body weight; more preferably about 10 ⁇ g/kg-100 ⁇ g/kg of body weight.
  • the dosage range is from about 0.7 ⁇ g- 350 mg; preferably about 700 ⁇ g-21 mg; most preferably about 700 ⁇ g-7 mg.
  • Dosages may be higher when the compounds are administered orally or transdermally as compared to, for example, i.v. administration.
  • the compounds may be administered as a single bolus dose, a dose over time, as in i.v. or transdermal administration, or in multiple dosages.
  • Subjects that will respond favorably to the method of the invention include medical and veterinary subjects generally, including human patients. Among other subjects for whom the methods of the invention is useful are cats, dogs, large animals, avians such as chickens, and the like. In general, any subject who has a WBC deficiency or, more generally, who would profit from the elevation of white blood cell count is appropriate for administration of the invention method.
  • Typical conditions which are ameliorated or otherwise benefited by the method of the invention include hematopoietic disorders, such as aplastic anemia, leukemias, drug-induced anemias, and hematopoietic deficits from chemotherapy or radiation therapy.
  • the method of the invention is also useful in enhancing the success of transplantation during and following immunosuppressive treatments as well as in effecting more efficient wound healing and treatment of bacterial inflammation.
  • the method of the present invention is further useful for treating subjects who are immunocompromised or whose immune system is otherwise impaired.
  • Typical conditions which are ameliorated or otherwise benefited by the method of the present invention include those subjects who are infected with a retro virus and more specifically who are infected with human immunodeficiency virus (HIV).
  • HIV human immunodeficiency virus
  • the method of the invention thus targets a broad spectrum of conditions characterized by a deficiency in white blood cell count, or which would benefit from elevation of said WBC count.
  • the subjects described in this example already contained an indwelling peripheral intravenous catheter.
  • the prescribed amount of AMD3100 was administered over 15 minutes by intravenous fusion in a single dose. Blood samples were obtained prior to the dose, and at various times up to 24 hours after dose administration.
  • the ability to enhance WBC count across various species and the use of various compounds of formula (1) is believed due to the similarity of action of this compound in its antiviral applications and a possible mechanism for enhancing WBC count.
  • the compounds of the invention are believed to exert their antiviral effects by inhibiting the binding of the second receptor for the HIN virus, CXCR-4, and thus to inhibit entry of the virus into the cell. These particular receptors appear homologous throughout a wide range of species, including mouse, rat, cat and man.
  • the ability to enhance WBC count across various species and the use of various compounds of formula (1) is believed due to the similarity of action of this compound in its antiviral applications and a possible mechanism for enhancing WBC count.
  • the compounds of the invention are believed to exert their antiviral effects by inhibiting the binding of the second receptor for the HIV virus, CXCR-4, and thus to inhibit entry of the virus into the cell. These particular receptors appear homologous throughout a wide range of species, including mouse, rat, cat and man.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods to elevate white blood cell counts in animal subjects using compounds of formula (1) are disclosed. These compounds have the formula: Z-linker-Z' or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula: -N(R)-(CR2)n-X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; 'linker' represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms; in an amount effective to elevate said WBC count in said subject.

Description

METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT
Technical Field The invention is in the field of therapeutics and medicinal chemistry. More particularly, the invention concerns methods to enhance white blood cell counts in subjects by administering certain cyclic polyamines.
Background Art White blood cells play a significant part in maintaining the health and viability of animals, including humans. These white blood cells include neutrophils, macrophage, and basophils/mast cells as well the B and T cells of the immune system. White blood cells are continuously replaced (as are red blood cells and clot forming cells) by the hematopoietic system in response to a number of growth factors, such as colony stimulating factors (CSF) and various cytokines. The nucleotide sequences encoding a number of these growth factors have been cloned and sequenced. Perhaps the most widely known of these is granulocyte colony stimulating factor (G-CSF) which has been approved for use in counteracting the negative effects of chemotherapy. A discussion of the hematopoietic effects of this factor can be found, for example, in U.S. Patent No. 5,582,823, incorporated in its entirety by reference herein.
While endogenous growth factors are pharmacologically effective, the well known disadvantages of employing proteins and peptides, as opposed to small molecules, as pharmaceuticals underlies the need to add to the repertoire of such growth factors compounds which are themselves small molecules. In another aspect, such small molecules are advantageous over proteins and peptides where production in large quantities are desired.
A number of cyclic polyamine antiviral agents have been described in a series of U.S. patents and applications over the last several years. These patents, U.S. Patent Nos. 5,021,409; 5,583,131; 5,698,546; and 5,817,807 are incorporated herein by reference. Also incorporated by reference is copending application Serial No.
09/111,895 filed 8 July 1998, which describes additional compounds. These patents describe the structural characteristics of the cyclic polyamine antiviral agents.
In addition, improved methods for preparation of some of these compounds are described in U.S. Patent Nos. 5,612,478; 5,756,728; 5,801,281; and 5,606,053. The disclosures of these U.S. patents are also incorporated herein by reference in their entirety.
It has now been found that the cyclic polyamine antiviral agents described in the above-mentioned patents have the effect of enhancing production of white blood cells as well as exhibiting antiviral properties. Thus, these agents are useful where treatment affects the activities within the bone marrow resulting in leukopenia, thus controlling the side-effects of chemotherapy, radiotherapy, enhancing the success of bone marrow transplantation, enhancing wound healing and burn treatment, as well as combating bacterial infections in leukemia. Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. Further, all documents referred to throughout this application are incorporated in their entirety by reference herein.
Disclosure of the Invention
The invention is directed to methods of treating animal subjects, in particular, veterinary and human patients, who are defective in white blood cell (WBC) count, or who would benefit from elevation of WBC levels. The methods of the invention employ cyclic polyamines including those described in the patents incorporated hereinabove by reference.
In one aspect, therefore, the invention is directed to a method to elevate the white blood cells (WBC) count, in a subject in need of such WBC elevation, which method comprises administering to said subject an amount of a compound of formula (1) or of a pharmaceutical composition thereof effective to elevate WBC levels.
In additional aspects, the invention is directed to pharmaceutical compositions containing the compound of formula (1) for use in effecting WBC count elevation in animal subject.
The compounds of formula (1) are of the formula:
Z-linker-Z' (1) wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms; said nitrogen atoms separated from each other by at least 2 carbon atoms, wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system.
Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula -N(R)-(CR2)n-X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and
X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; "linker" represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
The preferred forms of the compounds of the invention are discussed below.
Brief Description of the Drawings Figure 1 is a graph showing the response of individual human patients to intravenous administration of a compound of the invention.
Figure 2 is a graph showing the response in elevation of WBC counts observed in HIV-infected patients who received AMD-3100 by continuous infusion for up to 10 consecutive days. Modes of Carrying Out the Invention
The compounds useful in the invention are of the general formula set forth as formula (1) above. Certain embodiments are preferred; included among these are the compounds set forth in the above-incorporated U.S. patents. In general, preferred embodiments of Z and Z' are cyclic polyamine moieties having from 9-24C that include 3-5 nitrogen atoms. Particularly preferred are 1,5,9,13-tetraazacyclohexadecane; 1,5,8,11,14-pentaazacyclohexadecane; 1,4,8,11- tetraazacylotetradecane; 1 ,5,9-triazacylcododecane; 1 ,4,7, 10-tetraazacyclododecane; and the like, including such cyclic polyamines which are fused to an additional aromatic or heteroaromatic rings and/or containing a heteroatom other than nitrogen incorporated in the ring. Embodiments wherein the cyclic polyamine contains a fused additional cyclic system or one or more additional heteroatoms are described in U.S. Patent No. 5,698,546 incorporated hereinabove by reference. Also preferred are
3,7,l l,17-tetraazabicyclo(13.3.1)heptadeca-l(17),13,15-triene; 4,7,10,17-tetraazabicyclo(13.3.1)heptadeca-l(17),13,15-triene;
1 ,4,7, 10-tetraazacyclotetradecane; 1 ,4,7-triazacyclotetradecane; and
4,7, 10-triazabicyclo( 13.3.1 )heptadeca- 1 ( 17), 13 , 15-triene.
When Z' is other than a cyclic polyamine as defined in Z, its preferred embodiments are set forth in U.S. Patent No. 5,817,807, also incorporated hereinabove by reference.
Preferred forms of the linker moiety include those wherein the linker is a bond, or wherein the linker includes an aromatic moiety flanked by alkylene, preferably methylene moieties. Preferred linking groups include the methylene bracketed forms of 1,3-phenylene, 2,6-pyridine, 3,5-pyridine, 2,5-thiophene, 4,4'-(2,2'-bipyrimidine); 2,9-( 1 , 10-phenanthroline) and the like. A particularly preferred linker is 1,4- phenylene-bis-(methylene).
Particularly preferred embodiments of the compound of the formula (1) include 2,2'-bicyclam; 6,6'-bicyclam; the embodiments set forth in U.S. Patent No. 5,583,131, and in particular l,l'-[l,4-phenylene-bis(methylene)]-bis- 1,4,8,11- tetraazacyclotetradecane, set forth in U.S. Patent No. 5,021,409, and designated herein AMD3100.
Other preferred embodiments include
N-[ 1 ,4,8, 11 -tetraazacyclotetradecanyl- 1 ,4-phenylenebis(methylene)]-2- aminomethyl)pyridine;
7,7'-[l,4-phenylenebis(methylene)]bis-4,7,10,17-tetraazabicyclo-[13.3.1] heptadeca-l(17),13,15-triene;
7,7'-[l,4-phenylenebis(methylene)]bis-3,7,l l,17-tetraazabicyclo[13.3.1] heptadeca-l(17),13,15-triene; 1 , 1 '-[ 1 ,3-phenylenebis(methylene)]-bis- 1 ,4,8,11 -tetra-azacyclotetradecane;
1 , 1 '-[ 1 ,4-phenylenebis(methylene)]-bis- 1 ,4,8, 11 -tetra-azacyclotetradecane;
1 , l'-[ 1 ,4-phenylene-bis-(methylene)]-bis- 1 ,4,7, 10-tetraazacyclotetradecane;
1 , 1 '-[ 1 ,3-phenylene-bis-(methylene)]-bis- 1 ,4,7, 10-tetraazacyclotetradecane;
1 l,l l'-(l,2-propanediyl)bis-l,4,8,l 1 -tetraazacyclotetradecane; N-[4-( 1 ,4,7-triazacyclotetra-decane)- 1 ,4-phenylenebis(methylene)]-2-
(aminomethyl)pyridine;
N-[7-(4,7,10-triazabicyclo[13.3.1]heptadeca-l(17),13,15-triene)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine;
N-[7-(4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-l(17),13,15-triene)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; and
N-[4-[4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-l(17),13,15-triene]-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine.
Methods to synthesize the compounds useful in the method of the invention are set forth in the U.S. patents and application incorporated hereinabove by reference. The compounds of the invention may be prepared in the form of prodrugs, i.e., protected forms which release the compounds of the invention after administration to the subject. Typically, the protecting groups are hydrolyzed in body fluids such as in the bloodstream thus releasing the active compound or are oxidized or reduced in vivo to release the active compound. A discussion of prodrugs is found in Smith and Williams Introduction to the Principles of Drug Design, Smith, H.J.; Wright, 2nd ed., London (1988).
The compounds of the invention, as they are polyamines, may be administered prepared in the forms of their acid addition salts or metal complexes thereof. Suitable acid addition salts include salts of inorganic acids that are biocompatible, including HC1, HBr, sulfuric, phosphoric and the like, as well as organic acids such as acetic, propionic, butyric and the like, as well as acids containing more than one carboxyl group, such as oxalic, glutaric, adipic and the like. Typically, at physiological pH, the compounds of the invention will be in the forms of the acid addition salts. Particularly preferred are the hydrobromides. In addition, when prepared as purified forms, the compounds may also be crystallized as the hydrates.
The compounds of the invention may be administered as sole active ingredients, as mixtures of various compounds of formula (1), and/or in admixture with additional active ingredients that are therapeutically or nutritionally useful, such as antibiotics, vitamins, herbal extracts, antiinflammatori.es, glucose, antipyretics, analgesics, and the like.
The compounds of the invention may be formulated for administration to animal subject using commonly understood formulation techniques well known in the art. Formulations which are suitable for particular modes of administration and for compounds of the type represented by those of formula (1) may be found in
Remington's Pharmaceutical Sciences, latest addition, Mack Publishing Company, Easton, PA.
Preferably, the compounds are administered by injection, most preferably by intravenous injection, but also by subcutaneous or intraperitoneal injection, and the like. Additional parenteral routes of administration include intramuscular and intraarticular injection. For intravenous or parenteral administration, the compounds are formulated in suitable liquid form with excipients as required. The compositions may contain liposomes or other suitable carriers. For injection intravenously, the solution is made isotonic using standard preparations such as Hank's solution. Besides injection, other routes of administration may also be used. The compounds may be formulated into tablets, capsules, syrups, powders, or other suitable forms for administration orally. By using suitable excipients, these compounds may also be administered through the mucosa using suppositories or intranasal sprays. Transdermal administration can also be effected by using suitable penetrants and controlling the rate of release.
The formulation and route of administration chosen will be tailored to the individual subject, the nature of the condition to be treated in the subject, and generally, the judgment of the attending practitioner. Suitable dosage ranges for the compounds of formula (1) vary according to these considerations, but in general, the compounds are administered in the range of about 0.1 μg/kg-5 mg/kg of body weight; preferably the range is about 1 μg/kg - 300 μg/kg of body weight; more preferably about 10 μg/kg-100 μg/kg of body weight. For a typical 70-kg human subject, thus, the dosage range is from about 0.7 μg- 350 mg; preferably about 700 μg-21 mg; most preferably about 700 μg-7 mg.
Dosages may be higher when the compounds are administered orally or transdermally as compared to, for example, i.v. administration.
The compounds may be administered as a single bolus dose, a dose over time, as in i.v. or transdermal administration, or in multiple dosages. Subjects that will respond favorably to the method of the invention include medical and veterinary subjects generally, including human patients. Among other subjects for whom the methods of the invention is useful are cats, dogs, large animals, avians such as chickens, and the like. In general, any subject who has a WBC deficiency or, more generally, who would profit from the elevation of white blood cell count is appropriate for administration of the invention method.
Typical conditions which are ameliorated or otherwise benefited by the method of the invention include hematopoietic disorders, such as aplastic anemia, leukemias, drug-induced anemias, and hematopoietic deficits from chemotherapy or radiation therapy. The method of the invention is also useful in enhancing the success of transplantation during and following immunosuppressive treatments as well as in effecting more efficient wound healing and treatment of bacterial inflammation. The method of the present invention is further useful for treating subjects who are immunocompromised or whose immune system is otherwise impaired. Typical conditions which are ameliorated or otherwise benefited by the method of the present invention, include those subjects who are infected with a retro virus and more specifically who are infected with human immunodeficiency virus (HIV). The method of the invention thus targets a broad spectrum of conditions characterized by a deficiency in white blood cell count, or which would benefit from elevation of said WBC count. Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.
Example 1
Clinical Elevation of WBC Levels - Healthy Volunteers Eleven human patients having initial white blood cell counts of 4,000-6,500 cells/mm3 were used in the study. An intravenous dosing solution of AMD3100 (i.e., 1 , l'-[ 1 ,4-phenylene-bis(methylene)]-bis- 1 ,4,8, 11 -tetraazacyclotetradecane) were prepared from a stock solution which is a 1 mg/ml 1:10 dilution of a concentrate in
0.9% saline (normal saline) under sterile conditions. Aliquots from this stock solution were added to 50-ml bags of 0.9% saline for intravenous injection in amounts to achieve the desired dosage levels (10 μg/kg-80 μg/kg).
The subjects described in this example already contained an indwelling peripheral intravenous catheter. The prescribed amount of AMD3100 was administered over 15 minutes by intravenous fusion in a single dose. Blood samples were obtained prior to the dose, and at various times up to 24 hours after dose administration.
Eleven human subjects received intravenous administration of AMD-3100 at doses 10, 20, 40, and 80 μg/kg. Five subjects also received a single subcutaneous injection of AMD-3100 at doses of 40 and 80 μg/kg. The effect of AMD3100 given intravenously in these 11 human subject is shown in Figure 1. Three patients were administered dosages of 10 μg/kg (open circles); 3 patients were administered dosages of 20 μg/kg (solid circles); 3 patients were administered 40 μg/kg (open triangles); and 2 patients were administered 80 μg/kg (closed triangles).
As shown in Figure 1, all of the patients at all levels of administration showed a marked increase in white blood cell count over the succeeding 5-10 hours after administration which WBC count tapered off after about 24 hours, although not, in any case, returning to the original level. Generally, the levels of WBC correlate with the concentration levels of the compound in the bloodstream. For example, one patient who received 80 μg/kg experienced an enhancement of white blood cell count from 6,000 cells/mm3 to a peak value of 19,000 cells/mm3. Even the patient showing the least response, who was given 20 μg/kg, experienced an increase from about 6,300 cells/mm3 to about 9,000 cells/mm3. Thus, it appears that AMD3100 is consistently able to enhance WBC count in human patients.
While not intending to be bound by any theory, the ability to enhance WBC count across various species and the use of various compounds of formula (1) is believed due to the similarity of action of this compound in its antiviral applications and a possible mechanism for enhancing WBC count. The compounds of the invention are believed to exert their antiviral effects by inhibiting the binding of the second receptor for the HIN virus, CXCR-4, and thus to inhibit entry of the virus into the cell. These particular receptors appear homologous throughout a wide range of species, including mouse, rat, cat and man.
Example 2 Clinical Elevation of WBC Levels - HIV-Infected Patients Elevations in WBC counts have also been observed in HIV-infected patients who received AMD-3100 by continuous infusion for up to 10 consecutive days (Figure 2). Eight patients received AMD-3100 at infusion dose rates of 2.5 μg/kg/hr (patients 1-4) and 5.0 μg/kg/hr (patients 5-8). Elevations relative to the baseline were noted in samples taken on days 2, 6, and 11 (immediately prior to end of infusion) of the infusion period. Elevations in WBC count ratios (Day 11 samples) ranged from 1.4 to 2.8 times the baseline. WBC counts returned to baseline 7 days after discontinuation of the infusion. Thus, it appears that AMD3100 is consistently able to enhance WBC count following single dose or with continuous infusion in human patients.
While not intending to be bound by any theory, the ability to enhance WBC count across various species and the use of various compounds of formula (1) is believed due to the similarity of action of this compound in its antiviral applications and a possible mechanism for enhancing WBC count. The compounds of the invention are believed to exert their antiviral effects by inhibiting the binding of the second receptor for the HIV virus, CXCR-4, and thus to inhibit entry of the virus into the cell. These particular receptors appear homologous throughout a wide range of species, including mouse, rat, cat and man.

Claims

Claims
1. A method to treat a subject who would be benefited by elevation of white blood cell (WBC) count which method comprises administering to said subject an amount of a compound of the formula
Z-linker-Z' (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system;
Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula
-N(R)-(CR2)n-X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan;
"linker" represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms; in an amount effective to elevate said WBC count in said subject.
2. The method of claim 1 wherein Z and Z' are both cyclic polyamines.
3. The method of claim 1 wherein Z and Z' are identical.
4. The method of claim 1 wherein Z contains 10-24 members and contains 4 nitrogen atoms.
5. The method of claim 1 wherein Z and Z' are both 1,4,8,11- tetraazocyclotetradecane.
6. The method of claim 1 wherein the linker comprises an aromatic ring bracketed by two methylene moieties.
7. The method of claim 6 wherein the linker is 1,4-phenylene-bis- methylene.
8. The method of claim 7 wherein the compound of formula ( 1 ) is 1,1'-
[ 1 ,4-phenylene-bis-(methylene)-bis- 1 ,4,8, 11 -tetraazacyclotetradecane (AMD3100).
9. The method of claim 1 wherein the compound of formula (1) is
N-[ 1 ,4,8, 11 -tetraazacyclotetradecanyl- 1 ,4-phenylenebis(methylene)]-2- aminomethyl)pyridine;
7,7'-[ 1 ,4-phenylenebis(methylene)]bis-4,7, 10, 17-tetraazabicyclo-[ 13.3.1] heptadeca-l(17),13,15-triene;
7,7'-[ 1 ,4-phenylenebis(methylene)]bis-3 ,7,11,17-tetraazabicyclo[ 13.3.1] heptadeca- 1(17), 13, 15 -triene ; l,l'-[l,3-phenylenebis(methylene)]-bis-l,4,8,l 1 -tetra-azacyclotetradecane;
1 , l*-[ 1 ,4-phenylenebis(methylene)]-bis-l ,4,8, 11 -tetra-azacyclotetradecane;
1 , 1 '-[ 1 ,4-phenylene-bis-(methylene)]-bis- 1 ,4,7, 10-tetraazacyclotetradecane;
1 , 1 '-[1 ,3-phenylene-bis-(methylene)]-bis- 1 ,4,7, 10-tetraazacyclotetradecane;
11 , 11 '-( 1 ,2-propanediyl)bis- 1 ,4,8, 11 -tetraazacyclotetradecane; N-[4-( 1 ,4,7-triazacyclotetra-decane)- 1 ,4-phenylenebis(methylene)]-2-
(aminomethyl)pyridine;
N-[7-(4,7,10-triazabicyclo[13.3.1]heptadeca-l(17),13,15-triene)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine;
N-[7-(4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-l(17),13,15-triene)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; or N-[4-[4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-l(17),13,15-triene]-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine.
10. The method of claim 1 wherein formula (1) is in the form of its acid addition salt.
11. The method of claim 10 wherein the acid addition salt is the hydrobromide.
12. The method of claim 1 wherein the subject exhibits a hematopoietic deficit from chemotherapy or radiation therapy.
13. The method of claim 1 wherein the subject has a condition selected from the group consisting of aplastic anemia, leukemia and drug-induced anemia.
14. The method of claim 1 wherein the subject is a transplantation recipient.
15. The method of claim 1 wherein said elevation of WBC count enhances wound healing.
16. The method of claim 1 wherein said elevation of WBC count ameliorates bacterial inflammation.
17. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.
18. The method of claim 1 wherein the compound of formula (1) is administered to said subject in the dosage range of about 0.1 μg/kg-5 mg/kg of body weight.
19. A pharmaceutical composition comprising an effective amount of the compound of formula (1) as set forth in claim 1 in unit dosage form for elevating white blood cell count in a subject.
20. A method to stimulate the production of white blood cells (WBC) in an animal subject thereby elevating the WBC count which method comprises: administering to said subject an amount of a compound of the formula
Z-linker-Z' (1) or pharmaceutically acceptable salt thereof wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system; Z' may be embodied in a form as defined by Z above, or alternatively may be of the formula
-N(R)-(CR2)n-X wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan;
"linker" represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms; in an amount effective to elevate said WBC count in said subject.
21. The method of claim 1 or claim 20, wherein said subject is infected with a retro virus.
22. The method of claim 21 , wherein said retro virus is HIV.
23. The method of claim 1 or claim 20, wherein administering the compound of formula (1) to said subject is in a single dose or by continuous infusion.
PCT/CA2000/000104 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count WO2000045814A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CNB008033285A CN1310642C (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
NZ513602A NZ513602A (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
DE60011391T DE60011391T2 (en) 1999-02-02 2000-02-02 METHOD AND COMPOSITIONS FOR INCREASING THE NUMBER OF WHITE BLOOD CELLS
MXPA01007801A MXPA01007801A (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count.
AT00903441T ATE268597T1 (en) 1999-02-02 2000-02-02 METHODS AND COMPOSITIONS FOR INCREASE THE NUMBER OF WHITE BLOOD CELLS
JP2000596934A JP4968868B2 (en) 1999-02-02 2000-02-02 Methods and compositions for increasing white blood cell count
EP00903441A EP1148875B1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
BR0007924-3A BR0007924A (en) 1999-02-02 2000-02-02 Methods and compositions for increasing white blood cell count
CA2361587A CA2361587C (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
APAP/P/2001/002221A AP1497A (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count.
AU25278/00A AU772979B2 (en) 1999-02-02 2000-02-02 Methods to enhance white blood cell count
SI200030444T SI1148875T1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count
DK00903441T DK1148875T3 (en) 1999-02-02 2000-02-02 Methods and compositions for increasing the number of white blood cells
IL144400A IL144400A (en) 1999-02-02 2000-02-02 Use of compounds for preparation of a medicament for treatment of hematopoietic deficit from chemotherapy or radiation therapy
NO20013770A NO20013770L (en) 1999-02-02 2001-08-01 Methods and compositions to increase the number of white blood cells
HK02100103.2A HK1038319B (en) 1999-02-02 2002-01-07 Methods and compositions to enhance white blood cell count
AU2004203847A AU2004203847B2 (en) 1999-02-02 2004-08-13 Methods to enhance white blood cell count

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02
US60/118,225 1999-02-02

Publications (1)

Publication Number Publication Date
WO2000045814A1 true WO2000045814A1 (en) 2000-08-10

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000104 WO2000045814A1 (en) 1999-02-02 2000-02-02 Methods and compositions to enhance white blood cell count

Country Status (24)

Country Link
US (2) US6365583B1 (en)
EP (1) EP1148875B1 (en)
JP (2) JP4968868B2 (en)
KR (1) KR100643553B1 (en)
CN (1) CN1310642C (en)
AP (1) AP1497A (en)
AT (1) ATE268597T1 (en)
AU (2) AU772979B2 (en)
BR (1) BR0007924A (en)
CA (1) CA2361587C (en)
CZ (1) CZ20012698A3 (en)
DE (1) DE60011391T2 (en)
DK (1) DK1148875T3 (en)
ES (1) ES2222174T3 (en)
HK (1) HK1038319B (en)
HU (1) HUP0200100A3 (en)
IL (1) IL144400A (en)
MX (1) MXPA01007801A (en)
NO (1) NO20013770L (en)
NZ (1) NZ513602A (en)
PT (1) PT1148875E (en)
SI (1) SI1148875T1 (en)
TR (1) TR200102239T2 (en)
WO (1) WO2000045814A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044229A1 (en) * 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6489472B2 (en) 2000-09-29 2002-12-03 Anormed, Inc. Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
EP1411918A2 (en) * 2001-07-31 2004-04-28 Anormed Inc. Methods to mobilize progenitor/stem cells
US6825351B2 (en) 2001-09-12 2004-11-30 Anormed, Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
EP1631307A1 (en) * 2003-06-05 2006-03-08 Anormed Inc. Methods to mobilize progenitor/stem cells
EP1796716A2 (en) * 2004-08-13 2007-06-20 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
WO2012158707A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Use of cxcr4 antagonists
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CA2419219A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
ES2269465T3 (en) * 2000-09-15 2007-04-01 Anormed Inc HETEROCICLICAL COMPOUNDS OF UNION TO CHEMIOQUINE RECEPTORS.
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004020462A1 (en) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4 antagonist and use thereof
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
MXPA05011353A (en) * 2003-04-22 2005-11-28 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy.
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc Chemokine receptor binding compounds
CA2612325A1 (en) * 2005-06-15 2006-12-28 Anormed Inc. Chemokine receptor binding compounds
BRPI0614801A2 (en) * 2005-08-16 2009-05-19 Genzyme Corp chemokine receptor binding compounds
US20100035941A1 (en) * 2006-02-24 2010-02-11 Bridger Gary J Methods for increasing blood flow and/or promoting tissue regeneration
US20100178271A1 (en) * 2006-08-07 2010-07-15 Genzyme Corporation Combination Therapy
EP2094274A4 (en) * 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
JP5715622B2 (en) 2009-06-14 2015-05-07 バイオカイン セラピューティックス リミテッド Peptide therapy to increase platelet levels
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
KR20180063881A (en) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 Compositions and methods for the treatment of cancer
KR102033920B1 (en) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 How to treat acute myeloid leukemia
CN109187337A (en) * 2018-09-10 2019-01-11 南京工业职业技术学院 A method of screening obdurability FeAl crystal boundary

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434385A2 (en) * 1989-12-21 1991-06-26 Johnson Matthey Public Limited Company Use of macrocyclic nitrogen containing compounds for the treatment of retroviral infections
WO1995018808A1 (en) * 1994-01-11 1995-07-13 Johnson Matthey Public Limited Company Cyclic polyamines
US5582823A (en) * 1985-08-23 1996-12-10 Amgen Inc. Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
WO2000002870A1 (en) * 1998-07-08 2000-01-20 Anormed Inc. Antiviral macrocyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582823A (en) * 1985-08-23 1996-12-10 Amgen Inc. Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
EP0434385A2 (en) * 1989-12-21 1991-06-26 Johnson Matthey Public Limited Company Use of macrocyclic nitrogen containing compounds for the treatment of retroviral infections
WO1995018808A1 (en) * 1994-01-11 1995-07-13 Johnson Matthey Public Limited Company Cyclic polyamines
WO2000002870A1 (en) * 1998-07-08 2000-01-20 Anormed Inc. Antiviral macrocyclic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIDGER G J ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF PHENYLENEBIS(METHYLENE)-LINKED BIS-TETRAAZAMACROCYCLES THAT INHIBIT HIV REPLICATION. EFFECTS OF MACROCYCLIC RING SIZE AND SUBSTITUENTS ON THE AROMATIC LINKER", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 38, no. 2, 20 January 1995 (1995-01-20), pages 366 - 378, XP000196379, ISSN: 0022-2623 *
HUNT D W C ET AL: "PHOTOFRIN, BUT NOT BENZOPORPHYRIN DERIVATIVE, STIMULATES HEMATOPOIESIS IN THE MOUSE", IMMUNOPHARMACOLOGY,XX,ELSEVIER SCIENCE PUBLISHERS BV, vol. 26, no. 3, 1 November 1993 (1993-11-01), pages 203 - 212, XP000567096, ISSN: 0162-3109 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756391B2 (en) 1995-06-06 2004-06-29 Anormed, Inc. Antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US7160872B2 (en) 1996-06-06 2007-01-09 Anormed Inc. Methods to treat conditions mediated by chemokine receptors
US7709486B2 (en) 1998-07-08 2010-05-04 Genzyme Corporation CXCR4 antagonists
US6872714B1 (en) 1998-07-08 2005-03-29 Anormed Inc. Methods to modulate conditions mediated by the CXCR4 receptor
US7414065B2 (en) 1998-07-08 2008-08-19 Genzyme Corporation Methods to modulate conditions mediated by the CXCR4 receptor
US7022717B2 (en) 1999-12-17 2006-04-04 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US6667320B2 (en) 1999-12-17 2003-12-23 Anormed Chemokine receptor binding heterocyclic compounds
WO2001044229A1 (en) * 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6489472B2 (en) 2000-09-29 2002-12-03 Anormed, Inc. Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP2022787A1 (en) 2000-09-29 2009-02-11 Anormed Inc. Process for the preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP3632425A1 (en) * 2001-07-31 2020-04-08 Genzyme Global S.à.r.l. Methods to mobilize progenitor/stem cells
JP2008195730A (en) * 2001-07-31 2008-08-28 Anormed Inc Method for mobilizing progenitor/stem cell
NO336989B1 (en) * 2001-07-31 2015-12-14 Genzyme Corp Compound for use in a method of treating a hematopoietic deficiency from chemotherapy or radiation therapy in an individual
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP2371361B1 (en) 2001-07-31 2019-08-07 Genzyme Corporation Methods to mobilize progenitor/stem cells
EP1411918A4 (en) * 2001-07-31 2007-11-14 Anormed Inc Methods to mobilize progenitor/stem cells
EP1411918A2 (en) * 2001-07-31 2004-04-28 Anormed Inc. Methods to mobilize progenitor/stem cells
EP2371361A1 (en) * 2001-07-31 2011-10-05 Genzyme Global S.à.r.l. Methods to mobilize progenitor/stem cells
US6987102B2 (en) * 2001-07-31 2006-01-17 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20190216773A1 (en) * 2001-07-31 2019-07-18 Genzyme Corporation Methods to mobilize progenitor/stem cells
US7935692B2 (en) 2001-07-31 2011-05-03 Genzyme Corporation Methods to mobilize progenitor/stem cells
US7897590B2 (en) 2001-07-31 2011-03-01 Genzyme Corporation Methods to mobilize progenitor/stem cells
JP2004538303A (en) * 2001-07-31 2004-12-24 アノーメッド インコーポレイティド How to mobilize progenitor / stem cells
US6825351B2 (en) 2001-09-12 2004-11-30 Anormed, Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US7452994B2 (en) 2001-09-12 2008-11-18 Anormed, Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
US7135570B2 (en) 2001-09-12 2006-11-14 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
EP1631307A4 (en) * 2003-06-05 2008-03-26 Anormed Inc Methods to mobilize progenitor/stem cells
EP1631307A1 (en) * 2003-06-05 2006-03-08 Anormed Inc. Methods to mobilize progenitor/stem cells
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc Chemokine combinations to mobilize progenitor/stem cells
EP1796716A2 (en) * 2004-08-13 2007-06-20 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2008017025A3 (en) * 2006-08-02 2008-10-09 Genzyme Corp Combination therapy
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012158707A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Use of cxcr4 antagonists
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11219621B2 (en) 2015-12-22 2022-01-11 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11306088B2 (en) 2016-06-21 2022-04-19 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11780837B2 (en) 2016-06-21 2023-10-10 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11045461B2 (en) 2018-08-31 2021-06-29 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11672793B2 (en) 2018-08-31 2023-06-13 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12115156B2 (en) 2018-08-31 2024-10-15 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Also Published As

Publication number Publication date
US6670354B2 (en) 2003-12-30
HK1038319B (en) 2005-03-18
CZ20012698A3 (en) 2002-03-13
DE60011391D1 (en) 2004-07-15
AP2001002221A0 (en) 2001-09-30
CN1310642C (en) 2007-04-18
IL144400A0 (en) 2002-05-23
CA2361587C (en) 2010-04-20
HUP0200100A2 (en) 2002-05-29
NO20013770L (en) 2001-09-27
AU772979B2 (en) 2004-05-13
JP2011088937A (en) 2011-05-06
AU2004203847A1 (en) 2004-09-09
IL144400A (en) 2010-05-17
TR200102239T2 (en) 2002-01-21
DE60011391T2 (en) 2005-07-14
JP4968868B2 (en) 2012-07-04
BR0007924A (en) 2001-11-06
SI1148875T1 (en) 2004-12-31
ATE268597T1 (en) 2004-06-15
NO20013770D0 (en) 2001-08-01
KR100643553B1 (en) 2006-11-10
KR20010101896A (en) 2001-11-15
MXPA01007801A (en) 2003-06-04
PT1148875E (en) 2004-10-29
EP1148875A1 (en) 2001-10-31
US20020058653A1 (en) 2002-05-16
US6365583B1 (en) 2002-04-02
CA2361587A1 (en) 2000-08-10
AU2527800A (en) 2000-08-25
CN1338933A (en) 2002-03-06
NZ513602A (en) 2003-10-31
HUP0200100A3 (en) 2004-07-28
ES2222174T3 (en) 2005-02-01
EP1148875B1 (en) 2004-06-09
DK1148875T3 (en) 2004-10-18
HK1038319A1 (en) 2002-03-15
AP1497A (en) 2005-11-20
JP2002536329A (en) 2002-10-29
AU2004203847B2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
EP1148875B1 (en) Methods and compositions to enhance white blood cell count
EP2371361B1 (en) Methods to mobilize progenitor/stem cells
AU2002318927A1 (en) Methods to mobilize progenitor/stem cells
EP0820281B1 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses
US5514664A (en) 1,4-dihydropyridines for application in combatting resistance to drugs
EP1345604B1 (en) Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
AU2007202911A1 (en) Methods to enhance white blood cell count
CA2482687A1 (en) Treatment of mesothelioma
EP1203585B1 (en) Anti-ischemic agent
EP1707568B1 (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
JPH0522687B2 (en)
Piomelli Recent advances in the management of thalassemia
JPH05201876A (en) Agent for reducing adverse action of fk565
WO1997017966A1 (en) Hemoregulatory compounds
JPH04208224A (en) Antitumor agent
JPH0867637A (en) Prophylactic and therapeutic agent for hepatopathy
EP1716852A1 (en) A composition comprising campothecin or a campothecin derivative and an alkylating agent for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00803328.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 144400

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-2698

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2000903441

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 596934

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017009649

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007801

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2361587

Country of ref document: CA

Ref document number: 2361587

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/02239

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 25278/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 513602

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000903441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017009649

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2698

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000903441

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 25278/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017009649

Country of ref document: KR